Non-castrate metastatic prostate cancer: Have the treatment options changed?

Phillip L. Palmbos, Maha Hussain*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Over the past 7 decades androgen-deprivation therapy (ADT) has been the cornerstone of treatment for metastatic non-castrate prostate cancer (NCPC); however, the mechanisms to achieve this goal have evolved over time to include not only bilateral orchiectomy and estrogens, but also gonadotropin-releasing hormone (GnRH) agonists, antagonists, and the inclusion of androgen receptor (AR) blockade. Despite treatment with ADT, most men will progress to castrate-resistant prostate cancer (CRPC). Over the last decade many new treatment options for CRPC have emerged. These new treatments also could have a meaningful role earlier in NCPC. In this review, we outline the biologic drivers of NCPC, review current standard therapy available for NCPC, and discuss the evolving role of new therapeutics in metastatic disease.

Original languageEnglish (US)
Pages (from-to)337-346
Number of pages10
JournalSeminars in Oncology
Issue number3
StatePublished - Jun 1 2013

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Non-castrate metastatic prostate cancer: Have the treatment options changed?'. Together they form a unique fingerprint.

Cite this